Skip to main content
. 2019 Feb 26;28(13):2120–2132. doi: 10.1093/hmg/ddz044

Figure 5.

Figure 5

Sunitinib inhibits SHP-2–ERK1/2 and activates the STAT3 pathway in C2C12 cell line. C2C12 myoblasts treated with 500 nm Sunitinib in triplicate (N = 3) and taken at different time points to assess SHP-2–ERK1/2 inhibition and STAT3 activation. (A) Quantification of SHP-2 phosphorylation shows significant inhibition at 5 min lasting up to 15 min. (B) Quantification of SHP-2 phosphorylation shows significant inhibition continuing from 30 min to 1 h. (C) Quantification of ERK1/2 phosphorylation shows significant inhibition starting at 15 min post-treatment and lasting up to 1 h. (D) Quantification of ERK1/2 phosphorylation showing continued inhibition at 1.5 h with recuperating phosphorylation after 2 h of treatment. (E) Quantification of STAT3 phosphorylation showing activation after 1.5 h of treatment. (F) Quantification of α7B integrin shows a 1.5-fold increase in expression 48 h post-treatment. Data assessed for significance using one-way ANOVA and statistical significance of mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001.